Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.72 USD -1.16% Market Closed
Market Cap: 247.5B USD

Operating Margin
Merck & Co Inc

38.1%
Current
36%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.1%
=
Operating Profit
24.5B
/
Revenue
64.2B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Merck & Co Inc
NYSE:MRK
248B USD
38%
US
Eli Lilly and Co
NYSE:LLY
955.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
485.9B USD
27%
CH
Roche Holding AG
SIX:ROG
247.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
205.5B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
US
Pfizer Inc
NYSE:PFE
148B USD
29%
FR
Sanofi SA
PAR:SAN
103.5B EUR
24%
No Stocks Found

Merck & Co Inc
Glance View

Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.

MRK Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.1%
=
Operating Profit
24.5B
/
Revenue
64.2B
What is the Operating Margin of Merck & Co Inc?

Based on Merck & Co Inc's most recent financial statements, the company has Operating Margin of 38.1%.

Back to Top